Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.82 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NR5A1 | Q13285 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3168927 | 0.92 | PTGDR2 (0.84) | PTGDR2PTGDRLMNATP53MAPT | |
| SCHEMBL3168945 | 0.91 | PTGDR2 (1.00) | PTGDR2PTGDRMAPTPPARGPPARA | |
| SCHEMBL3174445 | 0.91 | PTGDR2 (1.00) | PTGDR2PTGDRMAPTPPARGPPARA | |
| SCHEMBL3165304 | 0.91 | PTGDR2 (1.00) | PTGDR2PTGDRMAPTPPARGPPARA | |
| SCHEMBL3168564 | 0.88 | PTGDR2 (0.94) | PTGDR2PTGDRMAPTPPARGPPARA | |
| SCHEMBL12678719 | 0.86 | PTGDR2 (0.79) | PTGDR2PTGDRPPARGPPARA | |
| SCHEMBL3164713 | 0.86 | PTGDR2 (0.61) | PTGDR2LMNAL3MBTL1TP53TSHR | |
| SCHEMBL3168930 | 0.85 | PTGDR2 (1.00) | PTGDR2PTGDRPPARGPPARA | |
| SCHEMBL3168669 | 0.85 | PTGDR2 (0.60) | PTGDR2LMNAL3MBTL1TP53TSHR | |
| SCHEMBL3174803 | 0.85 | PTGDR2 (0.80) | PTGDR2PTGDRL3MBTL1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PTGDR2 116/4885PTGDR 189/4885LMNA 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.